A Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis
Public ClinicalTrials.gov record NCT05896527. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of DC-806 in Participants With Moderate to Severe Plaque Psoriasis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This was a 12-week treatment, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to evaluate the efficacy and safety of DC-806 in participants with moderate to severe plaque psoriasis. This study evaluated the efficacy, safety, tolerability, and pharmacokinetics (PK) of multiple oral doses of DC-806 in participants with moderate to severe plaque psoriasis.
Study identification
- NCT ID
- NCT05896527
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 229 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 70 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 2, 2023 (Actual)
- Primary completion
- Mar 25, 2024 (Actual)
- Completion
- Mar 25, 2024 (Actual)
- Last update posted
- Apr 4, 2025
2023 – 2024
United States locations
- U.S. sites
- 13
- U.S. states
- 9
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| First OC Dermatology | Fountain Valley | California | 92708-3701 | — |
| Clinical Science Institute | Santa Monica | California | 90404-2120 | — |
| Driven Research LLC | Coral Gables | Florida | 33134-3901 | — |
| Kirsch Dermatology - Probity - PPDS | Naples | Florida | 34102-6538 | — |
| GCP Global Clinical Professionals, LLC | St. Petersburg | Florida | 33713-8012 | — |
| ForCare Clinical Research - CenExel FCR - PPDS | Tampa | Florida | 33613-1244 | — |
| The Indiana Clinical Trials Center, PC | Plainfield | Indiana | 46168-2792 | — |
| Dermatology Specialists Research - 501 S 2nd St | Louisville | Kentucky | 40202-2862 | — |
| DICE Therapeutics Study Site | New York | New York | 10003-3314 | — |
| Dermatologists of Southwest Ohio - Probity - PPDS | Mason | Ohio | 45040-4520 | — |
| Paddington Testing Company Inc | Philadelphia | Pennsylvania | 19103-4738 | — |
| Center for Clinical Studies - Webster | Webster | Texas | 77598-4927 | — |
| Virginia Clinical Research Inc | Norfolk | Virginia | 23502-3945 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 43 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05896527, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 4, 2025 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT05896527 live on ClinicalTrials.gov.